Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2026-01-14 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于上海宣泰医药科技股份有限公司修订2025年限制性股票激励计划（草案）之法律意见书
Regulatory Filings
2026-01-14 Chinese
董事会薪酬与考核委员会关于公司《2025年限制性股票激励计划（草案修订稿）》及其摘要的核查意见
Remuneration Information Classification · 95% confidence The document is a formal opinion from the Board's Remuneration and Assessment Committee regarding a draft revision of a 2025 restricted stock incentive plan. It references relevant laws and regulations governing stock incentive plans and confirms compliance and appropriateness of the plan. The content focuses on remuneration and incentive arrangements for executives and employees, which aligns with compensation and remuneration disclosures. The document is not an annual report, earnings release, or other financial report but specifically relates to executive compensation and stock incentive plans. Therefore, it fits the Remuneration Information category (DEF 14A). The document length is short and contains detailed committee opinions, not just an announcement, so it is not a report publication announcement or regulatory filing. Confidence is high due to clear focus on remuneration and stock incentive plan details.
2026-01-14 Chinese
2025年限制性股票激励计划实施管理办法（修订稿）
Board/Management Information Classification · 95% confidence The document is titled as the "2025 Restricted Stock Incentive Plan Implementation Management Measures (Revised Draft)" for Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It details the governance structure, procedures for granting and vesting restricted stock, rights and obligations of the company and incentive recipients, handling of changes, termination and amendment procedures, and accounting treatment related to the stock incentive plan. It is a detailed policy document about a stock incentive plan, focusing on governance, procedures, and accounting treatment rather than financial results or earnings. It does not contain financial statements or earnings data, nor is it an announcement or a brief summary. It is not a regulatory filing or certification. The content aligns with governance and management information related to stock incentive plans and corporate governance practices. Therefore, the most appropriate classification is Board/Management Information (MANG), as it relates to management policies and governance regarding stock incentives.
2026-01-14 Chinese
2025年限制性股票激励计划（草案修订稿）
Remuneration Information Classification · 95% confidence The document is a detailed draft of a 2025 restricted stock incentive plan for Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It includes legal references, detailed terms of the stock incentive plan, allocation of shares, conditions for granting and vesting, management structure, and performance criteria. The content is focused on the company's stock-based employee incentive program, including the issuance and management of restricted stock to employees and executives. This type of document is a formal plan related to equity compensation and is typically classified under governance or management information related to executive compensation and stock plans. It is not an annual report, earnings release, or regulatory filing about financial results. It is not a proxy solicitation or voting results announcement. It is not a merger or acquisition document. It is not a call transcript or presentation. It is not a dividend or capital change announcement. The document is a comprehensive plan about stock incentives, which falls under the category of Remuneration Information (DEF 14A) filings, as these filings detail compensation plans and stock incentive programs for executives and employees. Therefore, the appropriate classification is Remuneration Information (DEF 14A). The document length (15,000 characters) and detailed content confirm it is the plan itself, not just an announcement or summary.
2026-01-14 Chinese
2025年限制性股票激励计划（草案修订稿）摘要公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of a 2025 restricted stock incentive plan (股权激励计划) by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It includes extensive information about the stock incentive plan's purpose, legal basis, stock source, number of shares, pricing, eligibility, vesting conditions, performance targets, adjustment methods, and procedures for granting and vesting. The document is regulatory in nature, related to equity compensation and management incentives, and is not a financial report, earnings release, or management discussion. It is not a proxy solicitation or voting results announcement, but a formal disclosure of a stock incentive plan. This type of document fits best under the category of Capital/Financing Update (CAP), as it relates to changes in capital structure and equity incentives. The document length (15,000 characters) and detailed content confirm it is the plan itself, not just an announcement of a report. Therefore, the classification is CAP with high confidence.
2026-01-14 Chinese
自愿披露关于注射用硫酸艾沙康唑获得国家药品监督管理局批准的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the approval of a drug (injection of isavuconazole sulfate) by the National Medical Products Administration. It includes details about the drug, its registration, and potential impact on the company. The document is short (819 characters) and serves as a regulatory announcement about a product approval, not a financial report or management discussion. It does not contain financial statements, earnings data, or meeting information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-01-06 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.